Leverage Shares 2X Long CRM Daily ETF

$Salesforce(CRM.US)

Salesforce: Turnaround, or the death of SaaS?

Salesforce’s 22.6% jump looks less like a dead-cat bounce and more like the market finally giving AI-enabled SaaS credit. Q2 FY27 revenue rose 11% to US$11.35bn, while cRPO grew 14% to US$33.5bn. FY26 itself delivered US$41.5bn revenue, +10%, with strong cash generation.

The ClaudeForce partnership is important: Salesforce is embedding Claude into workflows rather than fighting AI head-on. AI product ARR has reportedly reached nearly US$3.9bn.

Stance: This looks more like a SaaS reset than its death. Fundamentals are improving, but after the surge, valuation has quickly rerated. Technically, the breakout is powerful, but $252 is now a major reference point; chasing here carries risk.

For an option writer, I’d favour 30–45 DTE covered calls, around 10–15% OTM, targeting Delta ≤0.20. With CRM around $252, September $280–290 calls offer a better assignment buffer; premiums around $0.15–$0.50 are currently indicated, depending on strike/liquidity.

Bottom line: own the turnaround, but sell calls patiently rather than chase the rally.

Not financial advice.$Salesforce(CRM.US)

I know what I’m talking about

It's coming to the end of the month - also where most of the major companies have already reported earnings. As expected, the earnings season has seen some companies rally after posting magnificent results while others slump after posting weaker guidance or simply just due to traders taking profit. It is important to monitor and read in depth into the earnings report of your holdings, but also sometimes the share price don't go as expected due to fear (of say higher capex for e.g.) or just because it was already priced in.